Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Type Condition

    Madison, WI

    Search
    Madison, WI
    Show Map
    Map View
    Madison, WI
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      193 Clinical Paid Trials near Madison, WI

      Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      LY4065967 for Healthy Subjects

      Madison, Wisconsin
      The purpose of this study is to investigate the absorption, metabolism, excretion, and bioavailability of LY4065967 in healthy male participants. This is a 2-part study. The study will last about 58 days for participants in Part 1 and about 60 days for participants in Part 2.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:18 - 55
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      16 Participants Needed

      Immunoglobulin G for Safety and Tolerability

      Madison, Wisconsin
      This study will evaluate the safety and tolerability of SC administration of IgG in healthy participants.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      82 Participants Needed

      Itraconazole + Rifampin for Healthy Subjects

      Madison, Wisconsin
      This study is conducted to assess the effect of itraconazole, rifampin, and acid-reducing agents on INCB161734 pharmacokinetics when administered orally in healthy participants.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular, Respiratory, Renal, Others
      Must Not Be Taking:PPIs, H2 Antagonists

      72 Participants Needed

      Phenytoin or Itraconazole for Drug Absorption Study

      Madison, Wisconsin
      The purpose of this study is to investigate the effect of coadministration of phenytoin or itraconazole on the pharmacokinetics of BGB-16673 in healthy participants.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Metabolic, Cardiovascular, Neurological, Others

      30 Participants Needed

      MK-8527 for Healthy Subjects

      Madison, Wisconsin
      The goal of this study is to learn how \[14C\]MK-8527 moves through a healthy person's body over time. Researchers will study how \[14C\]MK-8527 is absorbed by the body, broken down by the body, and how it leaves the body.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:18 - 55
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Cancer, Hepatitis B, Hepatitis C, HIV

      8 Participants Needed

      Diltiazem + MK-6916 for Healthy Subjects

      Madison, Wisconsin
      The goal of the study is to learn what happens to levels of MK-6916 in a healthy person's body over time. Researchers will compare what happens to MK-6916 in the body when it is given with or without another medicine called diltiazem.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:Cancer, Cardiac Arrhythmia, Hepatitis, Others

      40 Participants Needed

      Methamphetamine for Methamphetamine Use

      Madison, Wisconsin
      This study is being done to understand the metabolism and impairment profile of methamphetamine (meth). Meth exists as two chemical structures that are mirror images of each other: R-meth and S-meth. S-meth is a strong central nervous system stimulant and used to treat attention deficit disorder (ADD). R-meth is not a strong central nervous system stimulant and is available over-the-counter in nasal decongestant sprays.17 healthy participants will be enrolled for 3 study visits and on study for up to 12 weeks.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 1
      Age:21 - 64

      Key Eligibility Criteria

      Disqualifiers:Substance Use Disorder, Pregnancy, Others
      Must Not Be Taking:Mood Stabilizers, Sedatives

      17 Participants Needed

      PF-07985045 for Cancer

      Madison, Wisconsin
      The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer. This study also aims to find the best amount of study medication. This study is seeking participants who have solid tumors (a mass of abnormal cells that forms a lump or growth in the body) that: * are advanced (cancer that doesn't disappear or stay away with treatment) and * have a KRAS gene mutation (a change in the DNA of the KRAS gene that can cause cells to grow in very high numbers). This includes (but limited to) the following cancer types: * Non-Small Cell Lung Cancer (NSCLC): It's a type of lung cancer where the cells grow slowly but often spread to other parts of the body. * Colorectal Cancer (CRC): This is a disease where cells in the colon (a part of large intestine) or rectum grow out of control. * Pancreatic ductal adenocarcinoma (PDAC): This is a cancer that starts in the ducts of the pancreas but can spread quickly to other parts of the body. Pancreas is a long, flat gland that lies in the abdomen behind the stomach. Pancreas creates enzymes that help with digestion. It also makes hormones that can help control your blood sugar levels. All participants in this study will take the study medication (PF-07985045) as pill by mouth. This will be repeated for 21-day or 28-day cycles. Depending on which part of the study participants are enrolled into they will receive the study medication (PF-07985045 alone or in combination with other anti-cancer medications). These anti-cancer medications will be given in the study clinic by intravenous (IV) that is directly injected into the veins at different times (depending on the treatment) during the 21-day or 28-day cycle. Participants can continue to take the study medication (PF-07985045) and the combination anti-cancer therapy until their cancer is no longer responding. The study will look at the experiences of people receiving the study medicines. This will help see if the study medicines are safe and effective. Participants will be in this study for up to 4 years. During this time, the participants will come into the clinic for 1 to 4 times in each 21-day or 28-day cycle. After the participants have stopped taking the study medication (at about at 2 years) they will be followed for another two years to see how they are doing
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Pneumonitis, Autoimmune Disease, GI Disease, Others
      Must Not Be Taking:Steroids, Immunosuppressants

      190 Participants Needed

      Psilocybin for Emotional Wellbeing Decline

      Madison, Wisconsin
      The goal of this clinical trial is to learn about the role that inducing neuroplasticity (the brain's ability to adapt and change) plays in the behavioral effects of psilocybin in people who have experienced a mild decline in emotional wellbeing. Researchers will compare different doses of psilocybin combined with midazolam or placebo to see what dose induces increased wellbeing. Participants will: * Receive one of four possible combinations of medications * Undergo an MRI * Complete questionnaires * Undergo transcranial magnetic stimulation (TMS) and EEG
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Psychiatric Diagnosis, Suicidal Ideation, Hypertension, Others
      Must Not Be Taking:Psychotropic, CNS-altering

      60 Participants Needed

      ION269 for Down Syndrome at Risk of Alzheimer's Disease

      Madison, Wisconsin
      The primary purpose of this study is to evaluate the safety and tolerability of ION269 in adults with Down syndrome with evidence of brain amyloid positivity.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:35 - 55

      Key Eligibility Criteria

      Disqualifiers:Unstable Psychiatric Illness, Others

      1 Participants Needed

      BG-C137 for Cancer

      Madison, Wisconsin
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C137 alone and in combination with anticancer agents in participants with advanced solid tumors. The study will be conducted in two phases: Phase 1a (Monotherapy Dose Escalation, and Safety Expansion; Combination Dose Confirmation and Safety Expansion) and Phase 1b (Dose Expansion).
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Corneal Disorders, Brain Metastasis, ILD, Others
      Must Not Be Taking:Topoisomerase Inhibitors, FGFR2b-targeted ADCs

      168 Participants Needed

      BG-T187 for Cancer

      Madison, Wisconsin
      This is a first-in-human (FIH), Phase 1a/1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-T187 alone and in combination with other therapeutic agents in participants with advanced solid tumors.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Brain Metastasis, Active Hepatitis C, Others
      Must Not Be Taking:Steroids, Immune Suppressants

      87 Participants Needed

      LY3962673 for Pancreatic Cancer

      Madison, Wisconsin
      The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Active CNS Metastases, Cardiovascular Disease, Infections, Others

      630 Participants Needed

      LY3532226 for Obesity

      Madison, Wisconsin
      The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3532226 in participants with obesity. Blood tests will be performed to check how much LY3532226 gets into the bloodstream and how long it takes the body to eliminate it following weekly or monthly administration. Part A of the study will last approximately 16 weeks, excluding screening period. Part B of the study will last approximately 20 weeks, excluding the screening period. Part C of the study will last approximately 8 weeks, excluding the screening period.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Psychiatric Disorders, Gastric Surgery, Others
      Must Not Be Taking:Weight-loss Medications

      129 Participants Needed

      ALTA2618 for Cancer

      Madison, Wisconsin
      The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:KRAS, NRAS, HRAS, BRAF, Others
      Must Not Be Taking:PI3K Inhibitors, MTOR Inhibitors

      110 Participants Needed

      BH-30236 for Acute Myeloid Leukemia and Myelodysplastic Syndrome

      Madison, Wisconsin
      Study BH-30236-01 is a first-in-human (FIH), Phase 1/1b, open-label, dose escalation and expansion study in participants with relapsed/refractory acute myelogenous leukemia (R/R AML) or higher-risk myelodysplastic syndrome (HR-MDS). Phase 1, Part 1 Dose Escalation - Monotherapy will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of BH-30236 administered orally. Approximately 50 participants may be enrolled in Phase 1, Part 1 Dose Escalation - Monotherapy. Phase 1, Part 2 Dose Escalation - Combination with Venetoclax will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of BH-30236 administered as a combination therapy with venetoclax. Approximately 48 participants may be enrolled in Phase 1, Part 2 Dose Escalation - Combination with Venetoclax. Phase 1b (Dose Expansion) will follow Phase 1 to further understand the relationships among dose, exposure, toxicity, tolerability, and clinical activity. Up to 72 participants may be enrolled in Phase 1b of the study as a monotherapy or in combination with venetoclax.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Acute Promyelocytic Leukemia, Others
      Must Not Be Taking:CLK Inhibitors

      170 Participants Needed

      Orforglipron for Obesity

      Madison, Wisconsin
      The main purpose of this study is to see how much of orforglipron (study drug) gets into the bloodstream and how long it takes the body to get rid of it when given as capsules compared to tablets in healthy overweight and obese participants. The safety and tolerability (side effects) of orforglipron when given as capsules and tablets will also be evaluated. The study will be conducted in two parts, with part A and B lasting up to approximately 25 and 22 weeks each respectively, including the screening period.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Cardiovascular, Psychiatric, Others

      508 Participants Needed

      Rocatinlimab Delivery Methods in Healthy Participants

      Madison, Wisconsin
      The main objective of this study is to evaluate the pharmacokinetics (PK) of rocatinlimab given as a single subcutaneous (SC) autoinjector dose compared to vial in healthy participants.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:18 - 60

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      231 Participants Needed

      Ketamine-assisted Psychotherapy for PTSD

      Madison, Wisconsin
      The objectives of this study are to investigate the feasibility, tolerability, and preliminary efficacy of repeated ketamine-assisted psychotherapy sessions in adolescents with severe posttraumatic stress disorder. The study will enroll adolescents with a current diagnosis of posttraumatic stress disorder (PTSD) to complete three intravenous ketamine administrations accompanied by a psychotherapy session over the span of six weeks. All participants will complete an initial set of preparatory sessions, and each dosing session will be followed by three to six hours of integration sessions. Finally, participants will complete 7 nights of at-home sleep recordings. The investigators hypothesize that this protocol will be well-tolerated by adolescents and that patients will experience decreases in PTSD symptom severity at follow-up.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Early Phase 1
      Age:15 - 17

      Key Eligibility Criteria

      Disqualifiers:Psychotic Disorder, Bipolar, Autism, Others
      Must Not Be Taking:Benzodiazepines, Opiates, Lamotrigine

      5 Participants Needed

      Pembrolizumab + INCB081776 + Radiation for Head and Neck Cancer

      Madison, Wisconsin
      This study is evaluating INCB081776 when given in combination with the checkpoint inhibitor pembrolizumab and palliative radiation therapy in patients with metastatic or recurrent metastatic or recurrent head and neck squamous cell carcinoma (HNSCC). 12 participants will be enrolled and can expect to be on study for up to 12 months.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Early Phase 1

      Key Eligibility Criteria

      Disqualifiers:Auto-immune Disease, Genetic Conditions, Ophthalmologic Disorders, Others
      Must Not Be Taking:Immunosuppressants

      12 Participants Needed

      Why Other Patients Applied

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40
      Match to a Trial

      THC for Driving Performance

      Madison, Wisconsin
      This study is being done to assess the feasibility of administrating Δ9-THC and Δ8-THC isolates and simultaneously adopting several data harmonization measures to generate uniquely translatable data. This project aims to (1) evaluate the feasibility and acceptability of administering ∆9-THC and Δ8-THC isolates using standardized cannabis dosing units to quantify ∆9-THC and Δ8-THC pharmacokinetics; and (2) evaluate the feasibility and acceptability of adopting standardized impairment detection methods and driving performance definitions and measures on quantifying ∆9-THC and Δ8-THC driving impairment compared to a placebo.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Early Phase 1
      Age:18 - 49

      Key Eligibility Criteria

      Disqualifiers:Substance Use Disorder, Pregnancy, Others
      Must Not Be Taking:Mood Stabilizers, Sedatives

      5 Participants Needed

      Naporafenib + Trametinib for Solid Tumors

      Madison, Wisconsin
      This trial is testing two drugs, naporafenib and trametinib, to treat advanced cancers with a specific mutation (RAS Q61X). It targets patients whose cancers do not respond to standard treatments. The drugs work by blocking signals that cancer cells need to grow. Trametinib is used in treating various cancers.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:12 - 99

      Key Eligibility Criteria

      Disqualifiers:CNS Tumors, Retinal Vein Occlusion, Others
      Must Not Be Taking:CYP3A Inhibitors/inducers

      86 Participants Needed

      MT-601 for Lymphoma

      Madison, Wisconsin
      This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing).
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:CNS Pathology, HIV, Hepatitis, Others
      Must Not Be Taking:Immunosuppressants, Corticosteroids, Chemotherapy, Others

      79 Participants Needed

      CC-122 for Non-Hodgkin's Lymphoma

      Madison, Wisconsin
      This trial provides CC-122 treatment to participants who have benefited from it in previous trials for a long period. The study aims to monitor their safety and how well they tolerate the medication. CC-122 works by enhancing the immune system to fight diseases.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:No Clinical Benefit, Breastfeeding, Others
      Must Be Taking:CC-122

      12 Participants Needed

      CFT1946 + Trametinib for Solid Tumors

      Madison, Wisconsin
      The purpose of this study is to evaluate the safety and tolerability of CFT1946 as well as to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of CFT1946 as monotherapy (Arm A) and in combination with trametinib (CFT1946 + trametinib; Arm B) or Cetuximab (CFT1946 + cetuximab; Arm C).
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:CNS Involvement, Cardiac Disease, Diabetes, Others
      Must Be Taking:BRAF Inhibitors

      89 Participants Needed

      Targeted Radiotherapy for Brain Tumor

      Madison, Wisconsin
      The purpose of this dose finding study is to evaluate the safety and efficacy of 2 different dose levels of CLR 131 in children, adolescents and young adults with relapsed or refractory high-grade glioma (HGG).
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:10 - 25

      Key Eligibility Criteria

      Disqualifiers:HIV, Serious Infection, Cardiac Dysfunction, Others
      Must Not Be Taking:Antitumor Therapy

      50 Participants Needed

      JANX007 for Prostate Cancer

      Madison, Wisconsin
      This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Organ Transplant, Cardiovascular Disease, Infection, Others

      272 Participants Needed

      ASP3082 for Cancer

      Madison, Wisconsin
      This trial is testing a new drug called ASP3082 for adults with advanced cancers. The drug works by blocking harmful proteins. The study will determine the best dose and check for any side effects.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:CNS Metastases, Active Hepatitis, HIV, Others
      Must Not Be Taking:KRAS Inhibitors

      651 Participants Needed

      Lopinavir/Ritonavir for Anal Intraepithelial Neoplasia

      Madison, Wisconsin
      This trial is testing a suppository form of HIV medications lopinavir and ritonavir in patients with HIV who have a precancerous condition in the anal area. The goal is to see if these medications can safely reduce or clear the precancerous cells and HPV infection. Lopinavir and ritonavir are used together to treat HIV, with ritonavir making lopinavir more effective.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Low-grade Anal Dysplasia, Chemotherapy, Others
      Must Be Taking:HIV Antiretrovirals

      21 Participants Needed

      RLY-2608 + Fulvestrant for Breast Cancer

      Madison, Wisconsin
      This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, catalytic subunit alpha (PIK3CA) mutation in blood and/or tumor per local assessment. The study will evaluate RLY-2608 as a single agent for patients with unresectable or metastatic solid tumors. It will also evaluate RLY-2608 in combination RLY-2608 + fulvestrant and in triple combination RLY-2608 + fulvestrant + CDK4/6 inhibitor (palbociclib or ribociclib) or CDK4 inhibitor (PF-07220060) for patients with HR+ HER2- locally advanced or metastatic breast cancer. The RLY-2608 single agent arm, RLY-2608 + fulvestrant combination arm, and triple combination arms will have 2 parts: a dose escalation (Part 1) and a dose expansion (Part 2).
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Cardiovascular Disease, CNS Metastases, Others
      Must Be Taking:GnRH Agonist

      930 Participants Needed

      1...567

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do clinical trials in Madison, WI pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do clinical trials in Madison, WI work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Madison, WI 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Madison, WI is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Madison, WI several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a medical study in Madison, WI?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest clinical trials in Madison, WI?

      Most recently, we added Calfactant + Budesonide for Respiratory Distress Syndrome, Methamphetamine for Methamphetamine Use and Prazosin + MRI for Cerebrovascular Disease to the Power online platform.

      Popular Searches

      By Condition

      Depression Clinical Trials in Wisconsin

      Anxiety Clinical Trials in Wisconsin

      Schizophrenia Clinical Trials in Wisconsin

      ADHD Clinical Trials in Wisconsin

      Bipolar Disorder Clinical Trials in Wisconsin

      Multiple Sclerosis Clinical Trials in Wisconsin

      Autism Clinical Trials in Wisconsin

      Treatment Resistant Depression Clinical Trials in Wisconsin

      Borderline Personality Disorder Clinical Trials in Wisconsin

      Social Anxiety Disorder Clinical Trials in Wisconsin

      Parkinson's Disease Clinical Trials in Wisconsin

      Alzheimer's Disease Clinical Trials in Wisconsin

      By Location

      Clinical Trials near Milwaukee, WI

      Clinical Trials near Madison, WI

      Clinical Trials near Green Bay, WI

      Clinical Trials near Marshfield, WI

      Clinical Trials near La Crosse, WI

      Clinical Trials near Eau Claire, WI

      Clinical Trials near Stevens Point, WI

      Clinical Trials near Waukesha, WI

      Clinical Trials near Minocqua, WI

      Clinical Trials near Weston, WI

      Clinical Trials near Wausau, WI

      Clinical Trials near Marinette, WI

      Other People Viewed

      By Subject

      Top Clinical Trials near Madison, WI

      175 Clinical Trials near Elkhorn, WI

      86 Clinical Trials near Ashland, WI

      Top Clinical Trials near Germantown, WI

      Top Clinical Trials near Cudahy, WI

      Top Clinical Trials near Beloit, WI

      Top Clinical Trials near Appleton, WI

      Top Clinical Trials near Johnson Creek, WI

      Top Clinical Trials near Chippewa Falls, WI

      Top Clinical Trials near Brown Deer, WI

      Top Clinical Trials near Stevens Point, WI

      Top Clinical Trials near Janesville, WI

      By Trial

      Mental Health App for Depression in Cancer Survivors

      MRI-Guided Radiation for Early Breast Cancer

      Pembrolizumab + Chemotherapy + Radiation for Anal Cancer

      CMV-MVA Triplex Vaccine for CMV Complications Post-Transplant

      Mindfulness App for Hip Surgery Recovery

      Enhanced Support vs Standard Advice for Smoking Cessation in Veterans

      Rituximab + Stem Cell Transplant for Mantle Cell Lymphoma

      Visual and Acoustic Stimulation for Temperature Sensitivity

      High-Dose-Rate Brachytherapy for Prostate Cancer

      Valbenazine for Tardive Dyskinesia

      Imaging Techniques for Breast Cancer

      Lorazepam for Pain During IUD Insertion

      Related Searches

      Top Clinical Trials near San Diego, CA

      Technology Assisted Collaborative Care for Chronic Kidney Disease

      Cabozantinib for Pancreatic Neuroendocrine Tumors

      Dairy vs Plant-Based Beverages for Osteoporosis

      Auricular Neurostimulation for Opioid Use Disorder

      HIV Vaccine for HIV/AIDS

      Oral THC and CBD for Substance Use Disorders

      Palliative Care for Parkinson's Disease

      TriVerity Test for Infections

      Vitamin C for Insulin Resistance

      Silica 12CH for Silicosis

      TEV-48574 for Asthma